321-24-4Relevant articles and documents
Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety
Furukawa, Hideki,Miyamoto, Yasufumi,Hirata, Yasuhiro,Watanabe, Koji,Hitomi, Yuko,Yoshitomi, Yayoi,Aida, Jumpei,Noguchi, Naoyoshi,Takakura, Nobuyuki,Takami, Kazuaki,Miwatashi, Seiji,Hirozane, Yoshihiko,Hamada, Teruki,Ito, Ryo,Ookawara, Mitsugi,Moritoh, Yusuke,Watanabe, Masanori,Maekawa, Tsuyoshi
, p. 10352 - 10379 (2020/10/02)
GPR40/FFAR1 is a G-protein-coupled receptor expressed in pancreatic β-cells and enteroendocrine cells. GPR40 activation stimulates secretions of insulin and incretin, both of which are the pivotal regulators of glycemic control. Therefore, a GPR40 agonist
BCL-3 INHIBITORS
-
Paragraph 000700; 000701, (2016/04/06)
The present application relates to compounds of any one of Formulae I, Ia, Ib, Ic, Id, Ie, and If. Compounds of Formula (I) have the structure, wherein A, B, Y, Z, R2, R4, R5, R6, Rq and q are as defined herein. The compounds can be used as inhibitors of Bcl-3 and can be used for the treatment of cancer, particularly metastatic cancer.
AROMATIC COMPOUND
-
Paragraph 1297, (2016/05/19)
Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.